Advertisement

Annals of Nuclear Medicine

, Volume 29, Issue 2, pp 190–197 | Cite as

Clinical significance of diffuse hepatic uptake on post-therapeutic early and delayed 131I scan in differentiated thyroid cancer: a preliminary report

  • Jeong Won Lee
  • Sang Mi LeeEmail author
  • Jiyoun Choi
Original Article

Abstract

Objective

The purpose of this study was to investigate the clinical significance of diffuse hepatic uptake on post-therapeutic early and delayed 131I scan in patients with differentiated thyroid cancer (DTC).

Methods

We retrospectively analyzed 219 DTC patients who underwent high-dose 131I treatment and subsequent post-therapeutic dual 131I scan. Both early (third day after 131I treatment) and delayed (5–6th day after 131I treatment) 131I scan images were visually assessed and diffuse hepatic uptake was scored using a 4-point grading system depending on intensity.

Results

On early 131I scan, 73 patients (33.4 %) showed diffuse hepatic uptake, while 191 patients (87.2 %) patients showed diffuse hepatic uptake on delayed scan (p < 0.0001). The serum levels of ALT in patients with diffuse hepatic uptake on early scan were higher than those without diffuse hepatic uptake on early scan (p = 0.03 for ALT and p = 0.08 for AST). The serum levels of ALT and AST trended with the grade of hepatic uptake on delayed scan (p = 0.03 for ALT and p = 0.05 for AST). Diffuse hepatic uptake on early or delayed scan showed no significant relationship in the presence of thyroid remnants, metastatic DTC lesions, tumor recurrence during follow-up, and the serum thyroglobulin level (p > 0.05). On logistic regression analysis, both serum ALT (p = 0.01) and AST (p = 0.04) levels were significant predictive factors for diffuse hepatic uptake on early scan, while only serum ALT (p = 0.01) level was significant predictive factor for diffuse hepatic uptake on delayed scan.

Conclusions

The frequency of diffuse hepatic uptake on the delayed scan was significantly higher than the early scan. Diffuse hepatic uptake on early post-therapeutic scan and the intensity of diffuse hepatic uptake on delayed scan showed significant correlation with the serum levels of hepatic enzymes, but no significant association in the presence of thyroid remnants, metastatic DTC lesions, and tumor recurrence during follow-up. The timing and intensity of diffuse hepatic uptake on post-therapeutic scan may be related with factors such as hepatic function other than the thyroid tissue or DTC.

Keywords

Thyroid cancer Iodine-131 Post-therapeutic scan Diffuse liver uptake 

Notes

Acknowledgments

This work was supported in part by the Soonchunhyang University Research Fund.

Conflict of interest

No potential conflicts of interest were disclosed.

References

  1. 1.
    Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214.CrossRefPubMedGoogle Scholar
  2. 2.
    Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2004;89:3668–76.CrossRefPubMedGoogle Scholar
  3. 3.
    Fatourechi V, Hay ID, Mullan BP, Wiseman GA, Eghbali-Fatourechi GZ, Thorson LM, et al. Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer? Thyroid. 2000;10:573–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Souza Rosario PW, Barroso AL, Rezende LL, Padrao EL, Fagundes TA, Penna GC, et al. Post I-131 therapy scanning in patients with thyroid carcinoma metastases: an unnecessary cost or a relevant contribution? Clin Nucl Med. 2004;29:795–8.CrossRefPubMedGoogle Scholar
  5. 5.
    McDougall IR. Whole-body scintigraphy with radioiodine-131. A comprehensive list of false-positives with some examples. Clin Nucl Med. 1995;20:869–75.CrossRefPubMedGoogle Scholar
  6. 6.
    Ziessman HA, Bahar H, Fahey FH, Dubiansky V. Hepatic visualization on iodine-131 whole-body thyroid cancer scans. J Nucl Med. 1987;28:1408–11.PubMedGoogle Scholar
  7. 7.
    Rosenbaum RC, Johnston GS, Valente WA. Frequency of hepatic visualization during I-131 imaging for metastatic thyroid carcinoma. Clin Nucl Med. 1988;13:657–60.CrossRefPubMedGoogle Scholar
  8. 8.
    Chung JK, Lee YJ, Jeong JM, Lee DS, Lee MC, Cho BY, et al. Clinical significance of hepatic visualization on iodine-131 whole-body scan in patients with thyroid carcinoma. J Nucl Med. 1997;38:1191–5.PubMedGoogle Scholar
  9. 9.
    Ferris HA, Williams G, Parker JA, Garber JR. Therapeutic implications of diffuse hepatic uptake following I-131 therapy for differentiated thyroid cancer. Endocr Pract. 2013;19:263–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Omur O, Akgun A, Ozcan Z, Sen C, OzkiIic H. Clinical implications of diffuse hepatic uptake observed in postablative and post-therapeutic I-131 scans. Clin Nucl Med. 2009;34:11–4.CrossRefPubMedGoogle Scholar
  11. 11.
    Tatar FA, Morita E, Ituarte PH, Cavalieri RR, Duh QY, Price DC, et al. Association between residual thyroid carcinoma and diffuse hepatic uptake of 131I following radioiodine ablation in postoperative total thyroidectomy patients. World J Surg. 2001;25:718–22.CrossRefPubMedGoogle Scholar
  12. 12.
    Lee JW, Lee SM, Koh GP, Lee DH. The comparison of (131)I whole-body scans on the third and tenth day after (131)I therapy in patients with well-differentiated thyroid cancer: preliminary report. Ann Nucl Med. 2011;25:439–46.CrossRefPubMedGoogle Scholar
  13. 13.
    Lee JW, Lee SM, Lee DH, Kim YJ. Clinical utility of 18F-FDG PET/CT concurrent with 131I therapy in intermediate-to-high-risk patients with differentiated thyroid cancer: dual-center experience with 286 patients. J Nucl Med. 2013;54:1230–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Wakabayashi H, Nakajima K, Fukuoka M, Inaki A, Nakamura A, Kayano D, et al. Double-phase (131)I whole body scan and (131)I SPECT-CT images in patients with differentiated thyroid cancer: their effectiveness for accurate identification. Ann Nucl Med. 2011;25:609–15.CrossRefPubMedGoogle Scholar
  15. 15.
    Salvatori M, Perotti G, Villani MF, Mazza R, Maussier ML, Indovina L, et al. Determining the appropriate time of execution of an I-131 post-therapy whole-body scan: comparison between early and late imaging. Nucl Med Commun. 2013;34:900–8.PubMedGoogle Scholar
  16. 16.
    Lee SM, Lee JW, Kim SY, Han SW, Bae WK. Prediction of risk for symptomatic sialadenitis by post-therapeutic dual (131)I scintigraphy in patients with differentiated thyroid cancer. Ann Nucl Med. 2013;27:700–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Maayan ML, Eisenberg J, Lopez EM, Rothschild MA. Hepatic visualization after 131I in patients with thyroid carcinoma. N Engl J Med. 1976;295:1258–9.PubMedGoogle Scholar

Copyright information

© The Japanese Society of Nuclear Medicine 2014

Authors and Affiliations

  1. 1.Department of Nuclear MedicineCatholic Kwandong University International St. Mary’s HospitalIncheonKorea
  2. 2.Department of Nuclear MedicineSoonchunhyang University HospitalCheonanKorea

Personalised recommendations